92 related articles for article (PubMed ID: 18955054)
1. Cisplatin differently affects amino terminal and carboxyl terminal domains of HSP90.
Ishida R; Takaoka Y; Yamamoto S; Miyazaki T; Otaka M; Watanabe S; Komatsuda A; Wakui H; Sawada K; Kubota H; Itoh H
FEBS Lett; 2008 Nov; 582(28):3879-83. PubMed ID: 18955054
[TBL] [Abstract][Full Text] [Related]
2. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90.
Itoh H; Ogura M; Komatsuda A; Wakui H; Miura AB; Tashima Y
Biochem J; 1999 Nov; 343 Pt 3(Pt 3):697-703. PubMed ID: 10527951
[TBL] [Abstract][Full Text] [Related]
3. Structural studies on the co-chaperone Hop and its complexes with Hsp90.
Onuoha SC; Coulstock ET; Grossmann JG; Jackson SE
J Mol Biol; 2008 Jun; 379(4):732-44. PubMed ID: 18485364
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox.
Okada M; Itoh H; Hatakeyama T; Tokumitsu H; Kobayashi R
Biochem J; 2003 Sep; 374(Pt 2):433-41. PubMed ID: 12803546
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.
Burlison JA; Blagg BS
Org Lett; 2006 Oct; 8(21):4855-8. PubMed ID: 17020320
[TBL] [Abstract][Full Text] [Related]
6. Exposure of protein kinase motifs that trigger binding of Hsp90 and Cdc37.
Prince T; Matts RL
Biochem Biophys Res Commun; 2005 Dec; 338(3):1447-54. PubMed ID: 16269130
[TBL] [Abstract][Full Text] [Related]
7. Conformational switching of the molecular chaperone Hsp90 via regulated phosphorylation.
Soroka J; Wandinger SK; Mäusbacher N; Schreiber T; Richter K; Daub H; Buchner J
Mol Cell; 2012 Feb; 45(4):517-28. PubMed ID: 22365831
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Hsp90 cochaperone interactions reveals a novel mechanism for TPR protein recognition.
Chadli A; Bruinsma ES; Stensgard B; Toft D
Biochemistry; 2008 Mar; 47(9):2850-7. PubMed ID: 18211007
[TBL] [Abstract][Full Text] [Related]
9. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
[TBL] [Abstract][Full Text] [Related]
10. The non-canonical Hop protein from Caenorhabditis elegans exerts essential functions and forms binary complexes with either Hsc70 or Hsp90.
Gaiser AM; Brandt F; Richter K
J Mol Biol; 2009 Aug; 391(3):621-34. PubMed ID: 19559711
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of Hsp90 dimerization modulators.
Chiosis G; Aguirre J; Nicchitta CV
Bioorg Med Chem Lett; 2006 Jul; 16(13):3529-32. PubMed ID: 16621545
[TBL] [Abstract][Full Text] [Related]
12. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
13. The Hsp90 molecular chaperone: an open and shut case for treatment.
Pearl LH; Prodromou C; Workman P
Biochem J; 2008 Mar; 410(3):439-53. PubMed ID: 18290764
[TBL] [Abstract][Full Text] [Related]
14. Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation.
Cuyàs E; Verdura S; Micol V; Joven J; Bosch-Barrera J; Encinar JA; Menendez JA
Food Chem Toxicol; 2019 Oct; 132():110645. PubMed ID: 31254591
[TBL] [Abstract][Full Text] [Related]
15. A mass spectrometric and molecular modelling study of cisplatin binding to transferrin.
Khalaila I; Allardyce CS; Verma CS; Dyson PJ
Chembiochem; 2005 Oct; 6(10):1788-95. PubMed ID: 16196027
[TBL] [Abstract][Full Text] [Related]
16. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue.
McDowell CL; Bryan Sutton R; Obermann WM
Int J Biol Macromol; 2009 Oct; 45(3):310-4. PubMed ID: 19576239
[TBL] [Abstract][Full Text] [Related]
17. Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach.
Hartinger CG; Tsybin YO; Fuchser J; Dyson PJ
Inorg Chem; 2008 Jan; 47(1):17-9. PubMed ID: 18067289
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 and a tyrosine embedded in the Hsp90 recognition loop are required for the Fer tyrosine kinase activity.
Hikri E; Shpungin S; Nir U
Cell Signal; 2009 Apr; 21(4):588-96. PubMed ID: 19159681
[TBL] [Abstract][Full Text] [Related]
19. HSP90 regulates cell survival via inositol hexakisphosphate kinase-2.
Chakraborty A; Koldobskiy MA; Sixt KM; Juluri KR; Mustafa AK; Snowman AM; van Rossum DB; Patterson RL; Snyder SH
Proc Natl Acad Sci U S A; 2008 Jan; 105(4):1134-9. PubMed ID: 18195352
[TBL] [Abstract][Full Text] [Related]
20. C-terminal heat shock protein 90 modulators produce desirable oncogenic properties.
Wang Y; McAlpine SR
Org Biomol Chem; 2015 Apr; 13(16):4627-31. PubMed ID: 25711919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
